Helen Yates, Chief Executive of the Multiple Sclerosis Resource Centre (MSRC) said: “We truly hope that the research leads to a treatment for this very worrying and potentially life threatening condition. It is important that people affected by MS that are
Biogen Idec, Elan’s partner in the development and sale of Tysabri, is testing the efficacy of a malaria pill developed during the Vietnam war in treating progressive multifocal leukoencephalopathy (PML), the brain infection read more »
Multiple sclerosis (MS) in children is being recognized with increasing frequency. The first descriptions of MS in children were published by Charcot between 1829 and 1849, though it was not for another 50 years that MS in children was again described in the literature (Hanefeld, 2007). There are now several national programs focused read more »
I would like to explain to you why I haven’t posted very many articles on my blog for the past few months.
I had a relapse in October 2008 and just could not seem to get my sluggish brain to do any research with any amount of understanding. Then came Christmas and all the hubbub over that. Our family has decided to make our read more »
Was your MRI of your brain or you spine as well? Many MRI’s as done of only the brain where there may not be lesions. An MRI done of both the brain and the spine is much more definitive of MS. read more »
Visual problems are a common, often disabling symptom in MS and according to the National Multiple Sclerosis Society can affect over 40% of patients. The Impact of Visual Impairment Scale consists of 5 items that assess the extent to which various activities dependent upon vision are affected read more »
Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neuro-degeneration that occurs in persons with multiple sclerosis, researchers have shown read more »
1)
This site contains valuable information. I agree with that communication is key to successful pain
2)
Furthermore, SPMS has two stages: with relapses-still in the inflammatory stage and qualifies for Tysabri; without read more »
Clinical data suggests that Bayhill’s lead product candidate BHT-3009 induces the immune system to tolerize to, rather than attack, the MBP in the myelin sheath. BHT-3009 is a plasmid encoding MBP directed specifically at reprogramming read more »
In the development of new therapies for multiple sclerosis, there are occasions in which the results of a study surprise investigators and challenge their long-held beliefs about MS. A recent example is the evolving story concerning the development of a drug called rituximab as a treatment for MS, specifically read more »
